* PMV Pharmaceuticals Inc PMVP.OQ PMVP.O is expected
to show
no change in quarterly revenue when it reports results on May
10.
* Refinitiv's mean analyst estimate for PMV Pharmaceuticals
Inc
is for a loss of 41 cents per share. For the same quarter last
year, the company reported a loss of 29 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 11.0%
in the last three months.
* Wall Street's median 12-month price target for PMV
Pharmaceuticals Inc is $48, above its last closing price
of $12.01.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2022 -0.43 -0.40
Dec. 31 2022 -0.35 -0.35 -0.40 Missed -15.4
Sep. 30 2021 -0.30 -0.30 -0.33 Missed -9.4
Jun. 30 2021 -0.30 -0.28 -0.29 Missed -2.8
Mar. -0.24 -0.24 -0.26 Missed -8.3
31 2021
Dec. 31 2020 -0.57
Sep. 30 2020 -0.34 -0.34 -1.46 Missed -323.2
This summary was machine generated May 10 at 18:33 GMT. All
figures in US dollars unless otherwise stated